Your browser doesn't support javascript.
loading
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
Schreuer, Max; Jansen, Yanina; Planken, Simon; Chevolet, Ines; Seremet, Teofila; Kruse, Vibeke; Neyns, Bart.
Affiliation
  • Schreuer M; Department of Medical Oncology, UZ Brussel, Brussels, Belgium.
  • Jansen Y; Department of Medical Oncology, UZ Brussel, Brussels, Belgium.
  • Planken S; Department of Medical Oncology, UZ Brussel, Brussels, Belgium.
  • Chevolet I; Department of Medical Oncology, UZ Gent, Ghent, Belgium.
  • Seremet T; Department of Medical Oncology, UZ Brussel, Brussels, Belgium.
  • Kruse V; Department of Medical Oncology, UZ Gent, Ghent, Belgium.
  • Neyns B; Department of Medical Oncology, UZ Brussel, Brussels, Belgium. Electronic address: bart.neyns@uzbrussel.be.
Lancet Oncol ; 18(4): 464-472, 2017 04.
Article in En | MEDLINE | ID: mdl-28268064
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Proto-Oncogene Proteins B-raf / MAP Kinase Kinase 1 / Protein Kinase Inhibitors / Melanoma / Mutation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Proto-Oncogene Proteins B-raf / MAP Kinase Kinase 1 / Protein Kinase Inhibitors / Melanoma / Mutation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2017 Type: Article